Calamos Advisors’s ClearPoint Neuro CLPT Stock Holding History

Calamos Advisors’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,586	Closed	-$113K	–	954
2024 Q1	$113K	Buy	+16,586	New	+$116K	﹤0.01%	799

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Calamos Advisors's CLPT Position: Q2 2024 in Review

Calamos Advisors sold out of ClearPoint Neuro (CLPT) in Q2 2024, closing a stake of 16,586 shares — an estimated $113K sold.

Calamos Advisors first reported a position in CLPT in Q1 2024 and held it in 1 quarter. The position peaked at $113K in Q1 2024. 86 funds tracked by Wall St. Rank hold CLPT as of Q2 2024.

Calamos Advisors reported no remaining ClearPoint Neuro position as of Q2 2024 after selling out during the quarter.
Calamos Advisors sold 16,586 ClearPoint Neuro shares in Q2 2024, an estimated $113K.
Calamos Advisors first reported a position in ClearPoint Neuro in Q1 2024 and held it in 1 quarter.
Calamos Advisors's ClearPoint Neuro position peaked at $113K in Q1 2024.
86 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2024.

Based on Calamos Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.